| Krystal Humbard, PLMHP | |
|
20275 Honeysuckle Dr, Ste 103, Elkhorn, NE 68022-3962 | |
| (402) 933-5700 | |
| (402) 933-9998 |
| Full Name | Krystal Humbard |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 20275 Honeysuckle Dr, Elkhorn, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528435146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 10390 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Krystal Humbard, PLMHP 20275 Honeysuckle Dr, Ste 103, Elkhorn, NE 68022-3962 Ph: (402) 933-5700 | Krystal Humbard, PLMHP 20275 Honeysuckle Dr, Ste 103, Elkhorn, NE 68022-3962 Ph: (402) 933-5700 |
News Archive
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.
Health care providers are missing opportunities to improve teens' vaccination coverage, reports a new study in the Journal of Adolescent Health.
Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
Scientists have found that overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) blocks the formation of new blood vessels and thus reduces tumor growth. Therapeutics based on this finding may potentially lead to new cancer treatments.
› Verified 8 days ago
Diana M Meadors, LMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 540 S 205th St, Elkhorn, NE 68022 Phone: 402-601-1362 | |
Katrina Jo Bishop, PLADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1023 N 205th St, Elkhorn, NE 68022 Phone: 402-660-3225 | |
Ms. Jennie Lee Lacey-benson, PLMHP, MSE Counselor Medicare: Not Enrolled in Medicare Practice Location: 20650 Glenn St, Elkhorn, NE 68022 Phone: 402-289-2579 | |
Melissa Silva, PLMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 20275 Honeysuckle Dr, Suite 103, Elkhorn, NE 68022 Phone: 402-933-5700 Fax: 402-933-9998 | |
Alliea Bice, PLMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 20275 Honeysuckle Dr Ste 103, Elkhorn, NE 68022 Phone: 402-933-5700 Fax: 402-933-9998 | |
Amanda E Wells, PLMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 19534 Farnam St, Elkhorn, NE 68022 Phone: 402-981-2420 | |
Victoria Elizabeth Stegall, MA, LMHP, PLADAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1045 S 217th St, Elkhorn, NE 68022 Phone: 541-232-5506 |